EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity

Esther Osher, Ravit Geva, Ido Wolf, Karen Tordjman, Joseph Klausner, Yael Sofer, Erez Scapa, Oren Shibolet, Dana Ben-Ami Shor, Iddo Bar-Yishay, Nir Lubezky, Yaacov Goykhman und 7 weitere

Journal of Clinical & Translational Endocrinology · 2023-09 · 33 · 100322

DOI: 10.1016/j.jcte.2023.100322 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical & Translational Endocrinology, 2023-09. Verfasst von Esther Osher und 18 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Endocrinology, Metabolism, and Hypertension, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Pancreatic neuroendocrine tumors (PNETs) are rare, but their incidence has risen significantly in recent years. Whereas diabetes mellitus (DM) is recognized in association with chronic pancreatitis and pancreatic cancer, it has not been well-characterized concerning non-functioning (NF)-PNETs.Study aim: to determine whether NF-PNETs are associated with DM/ Pre-DM and characterize the features of this putative association.

Methods

Retrospective study to evaluate rate of Pre-DM /DM in subjects with NF-PNETs.

Results

Study cohort of 129 patients with histologically confirmed NF-PNETs, ∼60% were men (M/F: 77/52). Abnormal glucose metabolism that preceded any treatment was seen in 70% of this cohort: overt DM in 34% and Pre-DM in 36% of the subjects. However, during follow-up, the overall prevalence rose to 80.6%, owing exclusively to newly diagnosed DM in subjects who received treatment.Patients with DM/Pre-DM were older (65 ± 11; 54 ± 14; p < 0.0001), the tumor was more commonly localized in the pancreatic body and tail (76.5% vs. 23.5% p = 0.03), while BMI (27 ± 6 vs. 28 ± 5 kg/m2), and tumor size (2.4 ± 2 vs. 2.9 ± 3.2 cm) were similar. The relative prevalence of DM in our cohort of NF-PNETs was 1.6 higher than that in the age and gender-adjusted general Israeli population (95 %CI: 1.197-2.212p = 0.03).

Conclusions

We found a high rate of impaired glucose metabolism, either DM or Pre-DM, in a large cohort of NF-PNETs. The high prevalence of diabetes/pre-diabetes was unrelated to obesity or tumor size. This observation should increase awareness of the presence of DM on presentation or during treatment of "NF"-PNETs.

Schlagwörter

Stichwörter der Autor:innen

DysglycemiaNF-PNETType 3c diabetes mellitus

Autor:innen und Institutionen

  • Institute of Endocrinology, Metabolism, and Hypertension, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
  • Department of Oncology, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
  • Department of Surgery, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
  • Department of Gastroenterology, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
  • Institute of Pathology, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.
  • Insitute of Radiology, Tel Aviv-Sourasky Medical Center, Faculty of Medicine, Tel Aviv University, Israel.

Zitieren

APA

Osher, E., Geva, R., Wolf, I., Tordjman, K., Klausner, J., Sofer, Y., Scapa, E., Shibolet, O., Ben-Ami Shor, D., Bar-Yishay, I., Lubezky, N., Goykhman, Y., Lahat, G., Yakir, O., Pelles, S., Aizic, A., Blachar, A., Stern, N., & Greenman, Y. (2023). Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity. Journal of Clinical & Translational Endocrinology, 33, 100322. https://doi.org/10.1016/j.jcte.2023.100322

Vancouver

Osher E, Geva R, Wolf I, Tordjman K, Klausner J, Sofer Y, et al. Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity. Journal of Clinical & Translational Endocrinology. 2023;33:100322. doi:10.1016/j.jcte.2023.100322

BibTeX
@article{Osher2023,
  author = {Osher, Esther and Geva, Ravit and Wolf, Ido and Tordjman, Karen and Klausner, Joseph and Sofer, Yael and Scapa, Erez and Shibolet, Oren and Ben-Ami Shor, Dana and Bar-Yishay, Iddo and Lubezky, Nir and Goykhman, Yaacov and Lahat, Guy and Yakir, Oz and Pelles, Sharon and Aizic, Asaf and Blachar, Arye and Stern, Naftali and Greenman, Yona},
  title = {Dysglycemia in non-functioning pancreatic neuroendocrine tumors (NF-PNET): Further insights into an under recognized entity},
  journal = {Journal of Clinical & Translational Endocrinology},
  year = {2023},
  volume = {33},
  pages = {100322},
  doi = {10.1016/j.jcte.2023.100322}
}
Kostenlos starten →